# UNITED THERAPEUTICS Corp

Summary updated: 2026-10-02T11:40:25.509629Z
Canonical: https://finbar.com/research/companies/united-therapeutics-corp

## Overview

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused primarily on treatments for pulmonary hypertension and related lung diseases. Its marketed portfolio includes Tyvaso, Remodulin and Orenitram for pulmonary conditions, Unituxin for high-risk neuroblastoma, and Adcirca; the company also works on technologies intended to increase the availability of transplantable organs. [1](https://app.finbar.com/go?id=P55956413)[2](https://app.finbar.com/go?id=P56584140)[3](https://app.finbar.com/go?id=P68161096) Its stated public-benefit purpose is to advance therapies and technologies that address patients’ unmet medical needs and expand access to transplantable organs. [3](https://app.finbar.com/go?id=P68161096)

Founded in 1996, the company reported 2025 revenue of approximately $3.18 billion. [4](https://app.finbar.com/go?id=P69652352)[5](https://app.finbar.com/go?id=P10052865) At December 31, 2025, it had approximately 1,400 employees across 15 locations worldwide, with commercial activity extending beyond the United States through international distribution and sales. [6](https://app.finbar.com/go?id=P39279047)[7](https://app.finbar.com/go?id=P23249511)
[1](https://app.finbar.com/go?id=P55956413)[2](https://app.finbar.com/go?id=P56584140)[3](https://app.finbar.com/go?id=P68161096)[4](https://app.finbar.com/go?id=P69652352)[5](https://app.finbar.com/go?id=P10052865)[6](https://app.finbar.com/go?id=P39279047)[7](https://app.finbar.com/go?id=P23249511)

## Products & services

United Therapeutics’ pulmonary hypertension products include TYVASO, an inhaled treprostinil solution delivered four times daily through an ultrasonic nebulizer, and TYVASO DPI, a dry-powder treprostinil formulation delivered four times daily using single-use cartridges and a portable inhaler. Both are used for pulmonary arterial hypertension (PAH); TYVASO is also indicated for pulmonary hypertension associated with interstitial lung disease. [8](https://app.finbar.com/go?id=P88456603)[9](https://app.finbar.com/go?id=P68260303)[10](https://app.finbar.com/go?id=P38526625)[11](https://app.finbar.com/go?id=P25896333) REMODULIN is treprostinil injection for continuous subcutaneous or intravenous infusion to address PAH symptoms associated with exercise; its room-temperature stability, concentrated formulations and compatibility with company pump systems support ongoing infusion. ORENITRAM is an extended-release oral treprostinil tablet for PAH, indicated to delay disease progression and improve exercise capacity. [12](https://app.finbar.com/go?id=P86518041)[13](https://app.finbar.com/go?id=P45043723)[14](https://app.finbar.com/go?id=P53755652)[15](https://app.finbar.com/go?id=P55326848)[16](https://app.finbar.com/go?id=P70847371)

Other marketed products include UNITUXIN (dinutuximab), a monoclonal antibody used with other medicines to treat high-risk pediatric neuroblastoma following response to first-line therapy, and ADCIRCA (tadalafil), a PDE-5 inhibitor for PAH that the company commercially distributes in the United States. [2](https://app.finbar.com/go?id=P56584140)[17](https://app.finbar.com/go?id=P77116690)[18](https://app.finbar.com/go?id=P57962465) The company also provides fee-for-service ex-vivo lung perfusion to transplant centers through Lung Bioengineering, using the XVIVO Perfusion System to assess donor-lung function; the service may help make lungs that might otherwise go unused available for transplant. [19](https://app.finbar.com/go?id=P10014555)[20](https://app.finbar.com/go?id=P106699674)

For 2025, TYVASO products together accounted for 59% of total revenue, REMODULIN 17%, ORENITRAM 16% and ADCIRCA 1%. [21](https://app.finbar.com/go?id=P56185193)[12](https://app.finbar.com/go?id=P86518041)[16](https://app.finbar.com/go?id=P70847371)[17](https://app.finbar.com/go?id=P77116690)
[8](https://app.finbar.com/go?id=P88456603)[9](https://app.finbar.com/go?id=P68260303)[10](https://app.finbar.com/go?id=P38526625)[11](https://app.finbar.com/go?id=P25896333)[12](https://app.finbar.com/go?id=P86518041)[13](https://app.finbar.com/go?id=P45043723)[14](https://app.finbar.com/go?id=P53755652)[15](https://app.finbar.com/go?id=P55326848)[16](https://app.finbar.com/go?id=P70847371)[2](https://app.finbar.com/go?id=P56584140)[17](https://app.finbar.com/go?id=P77116690)[18](https://app.finbar.com/go?id=P57962465)[19](https://app.finbar.com/go?id=P10014555)[20](https://app.finbar.com/go?id=P106699674)[21](https://app.finbar.com/go?id=P56185193)

## Geographic presence

United Therapeutics’ reported revenue is concentrated in the United States. In 2025, it recorded $3,037.0 million in U.S. revenue (95.4%) and $145.7 million in rest-of-world revenue (4.6%). For the first half of 2026, the corresponding figures were $1,477.8 million (94.4%) and $87.0 million (5.6%). The company reports foreign revenue as rest of world rather than breaking it down by country. [22](https://app.finbar.com/go?id=T13156057)[23](https://app.finbar.com/go?id=T16734533)

The company identifies co-headquarters in Silver Spring, Maryland, and Research Triangle Park, North Carolina. Its Silver Spring campus includes laboratory and office space, product manufacturing and an ex-vivo lung perfusion center; its Research Triangle Park site includes research and development, manufacturing, warehousing and logistics operations. Other identified sites include an ex-vivo lung perfusion center in Jacksonville, Florida; a call-center facility in Melbourne, Florida; an aircraft-development facility in Bromont, Quebec; and the Organ Manufacturing Group in Manchester, New Hampshire. [24](https://app.finbar.com/go?id=P29836648)[25](https://app.finbar.com/go?id=P3217437)[26](https://app.finbar.com/go?id=P97361470)[27](https://app.finbar.com/go?id=P120648799)[28](https://app.finbar.com/go?id=P9231079)[29](https://app.finbar.com/go?id=P105720567)

The company’s locations information lists a workforce presence across the United States, Canada and the United Kingdom, but does not give an employee breakdown by country. [30](https://www.unither.com/about-us/locations)
[22](https://app.finbar.com/go?id=T13156057)[23](https://app.finbar.com/go?id=T16734533)[24](https://app.finbar.com/go?id=P29836648)[25](https://app.finbar.com/go?id=P3217437)[26](https://app.finbar.com/go?id=P97361470)[27](https://app.finbar.com/go?id=P120648799)[28](https://app.finbar.com/go?id=P9231079)[29](https://app.finbar.com/go?id=P105720567)[30](https://www.unither.com/about-us/locations)[30](https://www.unither.com/about-us/locations)

## Business segments

United Therapeutics reports one operating and reportable segment, managed on a consolidated basis. The segment focuses on developing and commercializing therapies for chronic and life-threatening conditions; the company does not report separate operating segments by product or therapeutic area. [31](https://app.finbar.com/go?id=P13748085)

As an analytical view—not a reported segment breakdown—FY2025 revenue was concentrated in pulmonary hypertension products: the Tyvaso franchise (Tyvaso DPI and nebulized Tyvaso) contributed about 59.0% of total revenue, Remodulin 16.6%, Orenitram 15.6%, Unituxin 7.1%, Adcirca 0.9%, and other products 0.8%. [32](https://app.finbar.com/go?id=T11490931) Tyvaso products treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease; Remodulin, Orenitram, and Adcirca are PAH therapies; Unituxin is used to treat neuroblastoma. [8](https://app.finbar.com/go?id=P88456603)[21](https://app.finbar.com/go?id=P56185193)[12](https://app.finbar.com/go?id=P86518041)[16](https://app.finbar.com/go?id=P70847371)[33](https://app.finbar.com/go?id=P62362945)[2](https://app.finbar.com/go?id=P56584140)
[31](https://app.finbar.com/go?id=P13748085)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[32](https://app.finbar.com/go?id=T11490931)[8](https://app.finbar.com/go?id=P88456603)[21](https://app.finbar.com/go?id=P56185193)[12](https://app.finbar.com/go?id=P86518041)[16](https://app.finbar.com/go?id=P70847371)[33](https://app.finbar.com/go?id=P62362945)[2](https://app.finbar.com/go?id=P56584140)

## Company history

United Therapeutics was incorporated in Delaware as Lung Rx, Inc. on June 26, 1996, founded by Martine Rothblatt to develop a treatment for pulmonary arterial hypertension (PAH); it adopted the United Therapeutics name in December 1997 and held its initial public offering on June 17, 1999. [4](https://app.finbar.com/go?id=P69652352)[34](https://ir.unither.com/faq) In 2002 and 2004, the FDA approved Remodulin for subcutaneous and intravenous infusion, respectively. [12](https://app.finbar.com/go?id=P86518041) The company added inhaled Tyvaso and Adcirca after FDA approvals in 2009. [35](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf)

In 2011, United Therapeutics acquired Revivicor, expanding its work into xenotransplantation and regenerative medicine. [36](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf) The FDA approved oral PAH treatment Orenitram in 2013, and in 2015 approved Unituxin for high-risk pediatric neuroblastoma; that year, founder Martine Rothblatt became co-CEO with Roger Jeffs. [37](https://ir.unither.com/press-releases/2013/12-20-2013-095453841)[2](https://app.finbar.com/go?id=P56584140)[38](https://app.finbar.com/go?id=P190496641) In 2021, the FDA expanded Tyvaso’s indication to pulmonary hypertension associated with interstitial lung disease, and the company converted to a public benefit corporation. [8](https://app.finbar.com/go?id=P88456603)[39](https://app.finbar.com/go?id=P52976535) The FDA approved Tyvaso DPI in 2022, while in 2024 United Therapeutics reported a first human transplant of its investigational thymokidney under compassionate-use authorization. [40](https://ir.unither.com/press-releases/2022/05-24-2022)[41](https://app.finbar.com/go?id=P10730759)
[4](https://app.finbar.com/go?id=P69652352)[12](https://app.finbar.com/go?id=P86518041)[2](https://app.finbar.com/go?id=P56584140)[38](https://app.finbar.com/go?id=P190496641)[8](https://app.finbar.com/go?id=P88456603)[39](https://app.finbar.com/go?id=P52976535)[41](https://app.finbar.com/go?id=P10730759)[34](https://ir.unither.com/faq)[35](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf)[36](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf)[37](https://ir.unither.com/press-releases/2013/12-20-2013-095453841)[40](https://ir.unither.com/press-releases/2022/05-24-2022)

## Sources

1. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P55956413)
2. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P56584140)
3. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P68161096)
4. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P69652352)
5. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P10052865)
6. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P39279047)
7. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P23249511)
8. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P88456603)
9. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P68260303)
10. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P38526625)
11. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P25896333)
12. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P86518041)
13. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P45043723)
14. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53755652)
15. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P55326848)
16. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P70847371)
17. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P77116690)
18. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P57962465)
19. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P10014555)
20. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P106699674)
21. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P56185193)
22. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=T13156057)
23. [UNITED THERAPEUTICS Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16734533)
24. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29836648)
25. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3217437)
26. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97361470)
27. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P120648799)
28. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P9231079)
29. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P105720567)
30. [www.unither.com](https://www.unither.com/about-us/locations)
31. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P13748085)
32. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=T11490931)
33. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P62362945)
34. [ir.unither.com](https://ir.unither.com/faq)
35. [ir.unither.com](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/annual-reports/2009-Annual-Report.pdf)
36. [ir.unither.com](https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-resources/quarterly-reports/2011/4Q1110K.pdf)
37. [ir.unither.com](https://ir.unither.com/press-releases/2013/12-20-2013-095453841)
38. [UNITED THERAPEUTICS Corp — Full financial report (2015 Y)](https://app.finbar.com/go?id=P190496641)
39. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P52976535)
40. [ir.unither.com](https://ir.unither.com/press-releases/2022/05-24-2022)
41. [UNITED THERAPEUTICS Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P10730759)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.